Nanoform and Orion collaborate on 'nanoformed' APIs

9 Mar 2020

Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.

Nanoform, an innovative nanoparticle medicine enabling company, and Orion Corporation, a Finnish pharmaceutical company, have announced a collaboration to apply the former's Controlled Expansion of Supercritical Solutions (CESS) technology to improve the bioavailability and solubility of selected early-development compounds, increasing the likelihood of drugs entering clinical development.

Nanoform and Orion collaborate on 'nanoformed' APIs

Many new chemical entities struggle to progress into clinical development due to their physico-chemical properties and respective solubility and bioavailability challenges. This issue is expected to exacerbate as molecular complexity increases in drug discovery.

Nanoform's CESS technology produces nanoformed "designed-for-purpose" API particles, as small as 10 nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability.

This collaboration with Nanoform presents an opportunity to enhance Orion's formulation process and provide poorly soluble molecules with a path to clinical trials.

Dr Juha Kiesvaara, VP Global Pharmaceutical Research at Orion Corporation, believes that using nanoparticles in the range that Nanoform can produce will provide them with a "great opportunity" to simplify the formulation process, develop optimal products and enable poorly soluble molecules to progress into clinic.

"Producing tailored nanoparticles smaller than 200 nm from solution, in a controlled and reproducible manner, with good yield and without the need for excipients is challenging to do by current pharmaceutical manufacturing techniques or processes. Now that Nanoform has a path to clinical development with their upcoming GMP facility we are excited to see how they can add value to Orion's drug development products," said Dr Juha Kiesvaara.

Read More

Related news

New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
European patent granted for amatoxin conjugates for tumor therapy

European patent granted for amatoxin conjugates for tumor therapy

31 Mar 2020

The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.

Read more 
ProBioGen selected for development and large-scale manufacturing services

ProBioGen selected for development and large-scale manufacturing services

24 Mar 2020

The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.

Read more 
Positive update on the development of new XF‐platform drug formulations

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more 
Alvotech and DKSH partner to bring key biosimilar to Asia

Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Read more 
Codexis and Takeda collaborate to advance novel gene therapies

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Read more 
Vaxxas HD-MAP to deliver vaccines directly to the skin

Vaxxas HD-MAP to deliver vaccines directly to the skin

17 Mar 2020

Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.

Read more 
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

16 Mar 2020

The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.

Read more 
Technique improves drug delivery system characterization

Technique improves drug delivery system characterization

16 Mar 2020

Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.

Read more 
Bristol Myers Squibb disappointed with failed late-stage combo drug trial

Bristol Myers Squibb "disappointed" with failed late-stage combo drug trial

9 Mar 2020

Phase III study evaluating Empliciti plus Revlimid and dexamethasone in patients with newly diagnosed, untreated multiple myeloma fails to meet primary endpoint.

Read more